Latest News & Features
Refine Search
Americas
The US Federal Trade Commission has published its annual report for 2012, in which it remains critical of “pay-for-delay” patent settlements. 24 April 2013
Big Pharma
The UK Office of Fair Trading has accused GlaxoSmithKline of abusing its market dominance and infringing UK competition law by paying rivals to delay releasing generic versions of its anti-depressant Seroxat. 19 April 2013
Americas
Japanese pharma Shionogi has brought a lawsuit against Hospira Inc to keep it from marketing a generic version of Shionogi’s Doribax, alleging it infringes one of the company’s patents. 19 April 2013
Americas
Swiss pharmaceutical firm Novartis has filed a lawsuit against Accord Healthcare, Fresenius Kabi and Hikma Farmaceutica for applying to market generic versions of its cancer drug Zometa. 17 April 2013
Americas
The US Supreme Court has heard oral arguments on whether genetic material is patent eligible subject matter. Jennifer Camacho, shareholder at Greenberg Traurig, reports on Monday's proceedings. 16 April 2013
Americas
Myriad Genetics will deliver an oral argument at the US Supreme Court today defending its patents covering isolated human gene sequences linked to breast and ovarian cancer. 15 April 2013
Americas
The US Patent and Trademark Office has announced the winners of its Patents for Humanity competition, which recognises patent owners and licensees addressing global health and development challenges. 12 April 2013
Asia
Merck is the latest multinational pharma company to suffer a setback in India, after failing to win an injunction against generic versions of two anti-diabetes drugs. 8 April 2013
Americas
The US Court of Appeals for the Federal Circuit has reversed a $482 million jury decision against Johnson & Johnson subsidiary Cordis, ruling that its Cypher stent did not infringe a patent held by radiologist Bruce Saffran. 8 April 2013
Asia
India’s Supreme Court has rejected pharmaceutical company Novartis’s application to patent an updated version of its leukaemia drug Glivec, agreeing with the Comptroller General that it lacked novelty. 3 April 2013